Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
OPDIVO (Bristol Myers Squibb)
(https://opdivo.com) 📸 Data Snapshot: May 31, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE OPDIVO® & OPDIVO Qvantig® (https://opdivo.com)
OPDIVO® & OPDIVO Qvantig®
Whether you're a new or continuing OPDIVO® or OPDIVO Qvantig® patient, find resources that can support you through a cancer diagnosis and during treatment. Access helpful resources and find assistance here. Please see Indication and Important Safety Information.
NAV_HEADER_HEADING_REPEATED_BODY Subcutaneous Injection Immunotherapy Treatment | OPDIVO Qvantig® (https://opdivo.com/subcutaneous-injection/)
Subcutaneous Injection Immunotherapy Treatment | OPDIVO Qvantig®
Learn more about OPDIVO Qvantig® as a subcutaneous injection immunotherapy treatment option for your fight against cancer. Please see Indication and Important Safety Information.
NAV_HEADER_REPEATED Advanced Kidney Cancer (RCC) Cancer Treatment | OPDIVO® or OPDIVO Qvantig® (https://opdivo.com/advanced-kidney-cancer/)
Advanced Kidney Cancer (RCC) Cancer Treatment | OPDIVO® or OPDIVO Qvantig®
OPDIVO® and OPDIVO Qvantig® are FDA-approved immunotherapies. This cancer treatment is the foundation for three different treatments to fight against RCC. Please see Indication and Important Safety Information.
NAV_HEADER_REPEATED Melanoma Skin Cancer Treatment | OPDIVO® or OPDIVO Qvantig® (https://opdivo.com/melanoma/)
Melanoma Skin Cancer Treatment | OPDIVO® or OPDIVO Qvantig®
OPDIVO® and OPDIVO Qvantig® are FDA-approved immunotherapies that can be used alone, or in combination with YERVOY®, to treat a type of skin cancer called melanoma for certain adults and children 12 years of age and older. Please see Indication and Important Safety Information.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://opdivo.com) OPDIVO® & OPDIVO Qvantig®
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary. †OPDIVO Qvantig is not indicated for co-administration with YERVOY® (ipilimumab). [IMG: Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.] [H3] Explore another way you may receive treatment You and your healthcare provider may have a choice between under-the-skin injections (subcutaneous injection) with OPDIVO Qvantig and intravenous (lV) infusions with OPDIVO Learn more → [IMG: Hands perusing OPDIVO® (nivolumab) patient resources.] [H3] Helpful patient resources Explore resources to help you along your treatment journey View resources → [IMG: Frequently asked questions about treatment with OPDIVO® (nivolumab).] [H3] Have questions about treatment? We have answers about getting treatment, monitoring, and more See FAQs → [IMG: Hands exploring cost information and financial help for OPDIVO® (nivolumab).] [H3] Cost information and financial help Find information about cost and access to OPDIVO Learn more → OPDIVO and OPDIVO Qvantig will not work for everyone. Individual results may vary.
SUB-PAGE (https://opdivo.com/subcutaneous-injection/) Subcutaneous Injection Immunotherapy Treatment | OPDIVO Qvantig®
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary. †OPDIVO Qvantig is not indicated for co-administration with YERVOY® (ipilimumab). [H2] OPDIVO Qvantig is delivered in as little as 3-5 minutes† OPDIVO Qvantig is an immunotherapy treatment that is delivered differently than OPDIVO IV. Both work with the immune system in the same way, but OPDIVO Qvantig doesn’t need to be administered at an infusion center and may be given at a doctor’s office or a site closer to home. Ask your doctor if a subcutaneous injection may be right for you. [IMG: A physician preparing to administer a subcutaneous injection of OPDIVO® Qvantig™ to a patient’s abdomen.] Given as an intravenous infusion directly into a vein using a needle or tube. Takes 30 minutes This refers only to the time it takes to receive treatment and does not account for all aspects of treatment. Actual time at the clinic may vary. May require a port A port is a small device that is surgically implanted and connected to a vein. When medication is administered, a needle connected to an IV tube is inserted into the port. Given as an injection by a healthcare professional under the skin in the stomach area (abdomen) or thigh area. Takes 3-5 minutes This refers only to the time it takes to give the injection and does not account for all aspects of treatment. Actual time at the clinic may vary. No port needed Since medication is injected under the skin and no access to a vein is required, a port is not necessary. Alone or with other therapies, OPDIVO Qvantig is FDA approved to treat many types of cancer. Please see full list of eligible cancer types below. OPDIVO Qvantig showed similar results and side effects to infusions of OPDIVO IV in a clinical trial 495 PEOPLE WITH PREVIOUSLY TREATED KIDNEY CANCER WERE STUDIED. NO MAJOR DIFFERENCES WERE OBSERVED in the amount of medicine that went into the bloodstream between OPDIVO Qvantig and OPDIVO IV OPDIVO Qvantig was studied in a clinical trial that showed similar results and side effects to infusions of OPDIVO. In the clinical trial, 495 people who had previously treated kidney cancer and had up to 2 therapies that didn't work were given either OPDIVO Qvantig injections or OPDIVO IV infusions. OPDIVO Qvantig injections and OPDIVO IV infusions were compared to check that the injection worked like the infusion. This was done by measuring the amount of medicine in the bloodstream after the medicines were given. †OPDIVO Qvantig injections are given by a healthcare provider in 3-5 minutes. This does not account for all aspects of treatment. Actual clinic time may vary. [H2] What types of cancer is OPDIVO Qvantig FDA approved to treat? See full indication list in the carousel at the top of the page. OPDIVO Qvantig is approved alone or in combination with other cancer medication for adults with the following cancers. Advanced kidney cancer: Previously untreated kidney cancer that has spread (advanced renal cell carcinoma) Previously untreated kidney cancer that has spread (advanced renal cell carcinoma) in combination with targeted therapy Previously treated kidney cancer that has spread (advanced renal cell carcinoma) Melanoma: OPDIVO Qvantig is approved alone for adults and children 12 and older with the following cancers. Melanoma that has spread or cannot be removed by surgery (advanced melanoma) Stage 2B or stage 2C melanoma after it has been completely removed by surgery Stage 3 or stage 4 melanoma after it has been completely removed by surgery Gastroesophageal cancer: Previously untreated advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma that tests positive for PD-L1 Previously untreated advanced or metastatic esophageal squamous cell cancer (ESCC) that tests positive for PD-L1 Esophageal or gastroesophageal junction (GEJ) cancer that has been treated with chemoradiation followed by surgery to help prevent it from coming back Bladder cancer: Bladder or urinary tract cancer after surgery Advanced cancer in the bladder or urinary tract Previously treated advanced bladder or urinary tract cancer Non-small cell lung cancer: Early-stage non-small cell lung cancer (NSCLC) before surgery Early-stage non-small cell lung cancer (NSCLC) before and after surgery Head and neck squamous cell cancer: Previously treated squamous cell cancer of the head and neck Colorectal cancer (MSI-H/dMMR): Advanced colorectal cancer Previously treated advanced colorectal cancer Liver cancer (hepatocellular carcinoma): Previously untreated advanced liver cancer Previously treated advanced liver cancer [H2] OPDIVO Qvantig® is an FDA-approved alternative for most types of cancer in adults that can be treated with OPDIVO® (nivolumab)*† [IMG: Icon] [H2] Is OPDIVO Qvantig right for me? Find out if OPDIVO Qvantig is right for you with answers to common questions people have about OPDIVO Qvantig. How is OPDIVO Qvantig different from OPDIVO? OPDIVO Qvantig is an under-the-skin injection of OPDIVO and hyaluronidase. OPDIVO Qvantig includes an enzyme (hyaluronidase) which improves the way medicines are absorbed into the body when injected under the skin. Otherwise, it still works the same way OPDIVO does with your immune system to help your body fight cancer. Another difference is that the OPDIVO Qvantig injection takes 3-5 minutes* compared to about 30 minutes for OPDIVO IV, so you will be finished with the administration faster.* Talk to your doctor to see if OPDIVO Qvantig is right for you. It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig may not be used in combination with ipilimumab. *A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment and does not include observation time. Actual clinic time may vary. Talk to your doctor to see if OPDIVO Qvantig is right for you; it is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig may not be used in combination with ipilimumab. What if I’ve already started on OPDIVO IV treatment? Can I switch? Your doctor can help you decide at any time during your treatment if you can switch to OPDIVO Qvantig from OPDIVO IV. You and your doctor can work together to decide if OPDIVO Qvantig may be right for you. What can I expect at my appointment? Your appointment will be similar to an OPDIVO IV appointment. Depending on decisions that you and your healthcare team have made about your treatment plan, your OPDIVO Qvantig appointment will generally have a few parts. Before your injection: Your healthcare team will do blood tests to check you for side effects Receiving your injection: Injection time is 3-5 minutes,* though actual time in the clinic may vary After your injection: Your healthcare team may monitor you for side effects The time between treatments will vary from 2-4 weeks. Your healthcare team will decide the time between doses and how many treatments you will receive. What resources are available to help me understand and get help with cost? Get information on pricing This information is not a substitute for talking to your healthcare provider because they are the best source of information about your condition. *Please note, treatment is delivered in 3-5 minutes. This refers only to the time it takes to give the injection and does not account for all aspects of treatment. Actual time at the clinic may vary. †OPDIVO Qvantig is not indicated for co-administration with YERVOY® (ipilimumab). Download FAQ document [H1] “Every second counts” [IMG: A commercial for OPDIVO Qvantig®, an injectable immunotherapy treatment delivered in 3-5 minutes. A chance to live longer.] [H1] Katy's Story [H6] Katy, a real patient, is a retired school teacher. With her husband by her side, hear about Katy's journey from the moment of her diagnosis of metastatic melanoma to her treatment experience with OPDIVO Qvantig as an alternative to OPDIVO IV. [IMG: Katy, a real patient, shares the story of her diagnosis of metastatic melanoma and her treatment with OPDIVO Qvantig® (nivolumab + hyaluronidase‑nvhy).] [IMG: Two arms embracing to form a heart, signifying how the OPDIVO with You program may provide support for patients.] [H3] Sign up for support Learn more about the complimentary OPDIVO with You support program Sign up now → [IMG: image] [H3] Side effects tracker Track your symptoms and other important information so that you can proactively manage potential side effects with your doctor Get the side effect tracker → [IMG: Two arms embracing to form a heart, signifying how the OPDIVO with You program may provide support for patients.] [H3] Medication guide See which cancer types can be treated with OPDIVO Qvantig and possible side effects View medication guide →
SUB-PAGE (https://opdivo.com/advanced-kidney-cancer/) Advanced Kidney Cancer (RCC) Cancer Treatment | OPDIVO® or OPDIVO Qvantig®
*A 3-5 minute injection time of OPDIVO Qvantig compared to 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary. †OPDIVO Qvantig is not indicated for co-administration with YERVOY® (ipilimumab) or in pediatric patients. RCC=renal cell carcinoma. [H5] Advanced kidney cancer (renal cell carcinoma) OPDIVO + YERVOY is a treatment option for certain adults with previously untreated kidney cancer that has spread (advanced RCC) OPDIVO Qvantig is a treatment option for certain adults with kidney cancer that has spread (advanced RCC), after completing combination treatment with intravenous OPDIVO + YERVOY Clinical trial results → Getting treatment → [H5] Advanced kidney cancer (renal cell carcinoma) that may benefit from targeted therapy OPDIVO, in combination with CABOMETYX® (cabozantinib), is a treatment option for certain adults with previously untreated kidney cancer that has spread (advanced RCC) OPDIVO Qvantig, in combination with CABOMETYX, is a treatment option for certain adults with previously untreated kidney cancer that has spread (advanced RCC) Clinical trial results → Getting treatment → [H5] Previously treated kidney cancer (renal cell carcinoma) OPDIVO is a treatment option for certain adults with kidney cancer (also known as renal cell carcinoma or RCC) when your cancer has spread or grown after treatment with other cancer medications OPDIVO Qvantig is a treatment option for certain adults with kidney cancer (RCC) when your cancer has spread after treatment with other cancer medications Clinical trial results → Getting treatment → [IMG: See treatment plans and what to expect from an OPDIVO® IV infusion or OPDIVO® QVANTIG™ subcutaneous injection.] [H5] Explore another way you may receive treatment You and your healthcare provider may have a choice between under-the-skin injections (subcutaneous injection) with OPDIVO Qvantig and intravenous (lV) infusions with OPDIVO Learn more → OPDIVO Qvantig cannot be used in combination with YERVOY. OPDIVO, OPDIVO-based combination treatments, OPDIVO Qvantig, and OPDIVO Qvantig-based combination treatments will not work for everyone. Individual results may vary. [IMG: Man exploring real patients stories of experiences with OPDIVO® (nivolumab) or other OPDIVO-based combinations.] [H3] Patient stories Real patients share their experiences with OPDIVO and OPDIVO-based treatments Watch videos → [IMG: Frequently asked questions about treatment with OPDIVO® (nivolumab).] [H3] Have questions about treatment? We have answers about getting treatment, monitoring, and more See FAQs → [IMG: Hands exploring cost information and financial help for OPDIVO® (nivolumab).] [H3] Cost information and financial help Find information about cost and access to OPDIVO Learn more →
SUB-PAGE (https://opdivo.com/melanoma/) Melanoma Skin Cancer Treatment | OPDIVO® or OPDIVO Qvantig®
*A 3-5 minute injection time of OPDIVO Qvantig compared to 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary. †OPDIVO Qvantig is not indicated for co-administration with YERVOY. [H3] Advanced melanoma OPDIVO + YERVOY is a treatment option for adults and children 12 years of age and older with previously untreated advanced melanoma OPDIVO Qvantig is a treatment option for adults with previously untreated advanced melanoma after completing combination treatment with intravenous OPDIVO + YERVOY Clinical trial results → Getting treatment → [H3] Advanced melanoma OPDIVO is a treatment option for adults and children 12 years of age and older with previously untreated advanced melanoma OPDIVO Qvantig is a treatment option for adults with previously untreated advanced melanoma Clinical trial results → Getting treatment → [H3] Stage 2B or Stage 2C melanoma after surgery OPDIVO is a treatment option for adults and children 12 years and older to help prevent melanoma from coming back after it has been completely removed by surgery OPDIVO Qvantig is a treatment option for adults to help prevent melanoma from coming back after it has been completely removed by surgery Clinical trial results → Getting treatment → [H3] Stage 3B/C or Stage 4 melanoma after surgery OPDIVO is a treatment option for adults and children 12 years and older to help prevent melanoma from coming back after it has been completely removed by surgery OPDIVO Qvantig is a treatment option for adults to help prevent melanoma from coming back after it has been completely removed by surgery Clinical trial results → Getting treatment → [IMG: See treatment plans and what to expect from an OPDIVO® IV infusion or OPDIVO® QVANTIG™ subcutaneous injection.] [H5] Explore another way you may receive treatment You and your healthcare provider may have a choice between under-the-skin injections (subcutaneous injection) with OPDIVO Qvantig and intravenous (lV) infusions with OPDIVO Learn more → OPDIVO Qvantig cannot be used in combination with YERVOY. OPDIVO, OPDIVO + YERVOY, and OPDIVO Qvantig will not work for everyone. Individual results may vary. [IMG: Man exploring real patients stories of experiences with OPDIVO® (nivolumab) or other OPDIVO-based combinations.] [H3] Patient stories Real patients share their experiences with OPDIVO and OPDIVO-based treatments Watch videos → [IMG: Frequently asked questions about treatment with OPDIVO® (nivolumab).] [H3] Have questions about treatment? We have answers about getting treatment, monitoring, and more See FAQs → [IMG: Hands exploring cost information and financial help for OPDIVO® (nivolumab).] [H3] Cost information and financial help Find information about cost and access to OPDIVO Learn more →
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 9 | 0 |
| /subcutaneous-injection/ | 10 | 0 |
| /advanced-kidney-cancer/ | 9 | 0 |
| /melanoma/ | 9 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: OPDIVO (Bristol Myers Squibb) (opdivo.com)
OPDIVO delivers high-substance clinical information but fails forensically by trapping its proof in a closed-loop system without technical authority markers. It is a scientifically legitimate site that suffers from an ‘authority vacuum’ caused by the complete lack of schema and external verification links. The BS is low, but the ‘Trust Theatre’ is high due to the unverified review counts.
Immediately implement Organization and Product schema to link the website to the official Bristol Myers Squibb corporate identity. Replace generic ‘Patient Stories’ headers with specific trial identifiers (e.g., ‘Checkmate-67T results’) to increase information density. Add direct outbound links to PubMed or ClinicalTrials.gov for every efficacy claim made on the subcutaneous-injection page. Map the ‘Medication Guide’ and ‘Side effects tracker’ to specific technical documentation to move beyond the template fingerprint.
The content perfectly aligns with the Pharma & Biotech sector, focusing on immunotherapy (nivolumab) and subcutaneous delivery systems (hyaluronidase-nvhy). The presence of heavy regulatory disclaimers, indication lists, and clinical trial citations (495 people study) confirms its status as a high-compliance pharmaceutical product site.
“The score of 36 is driven primarily by technical authority gaps (Step 5) and the trust theatre flag (Step 3). The high review count without verifiable proof links is the single largest contributor to the BS score. Despite these technical failures, the semantic coherence and unique value proposition keep the score firmly in the 'Low BS' category compared to typical marketing sites.”
This training module utilizes a snapshot of public data from OPDIVO (Bristol Myers Squibb), captured on May 31, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to OPDIVO (Bristol Myers Squibb): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://opdivo.com to view the most current version of its content and learn from the source what this company is about and what it offers.